The relapse, TRM, OS and DFS among the patients in all patients. (A) Cumulative incidence of relapse. (B) Cumulative incidence of transplant-related mortality (TRM). (C) Overall survival (OS). (D) Disease-free survival (DFS). The patients without MRD post-HSCT were assigned to group A (n=709); the patients with MRD post-HSCT and receiving IL-2 treatment were assigned to group B (n=49); the patients with MRD post-HSCT and receiving DLI were assigned to group C (n=56). 1* represents the P value of comparison between group B and C; 2* represents the P value of comparison between group A and C; and 3* represents the P value of comparison among three group.